Cross-section of light micrographs showing cholesterol-containing plaques in the cardiac artery
Nigel Downer/Science Photo Library
The outlook for one-off treatments has brightened up the risk of heart disease for a person for the rest of their lives. In the first trial, a single dose of CRISPR gene editing therapy reduced cholesterol levels without serious side effects.
The Heart-2 trial, hosted by Boston biotechnology company Verve Therapeutics, involved 14 people who had inherited conditions that lead to extremely high cholesterol or developed heart disease at a young age. This was an early stage test…
Source: www.newscientist.com
Discover more from Mondo News
Subscribe to get the latest posts sent to your email.